Prevalence of current asthma and use of medication for asthma in the random sample at European Community Respiratory Health Survey III per participating country
| Subjects | Current asthma | SABA | LABA# | ICS# | Any medication | |
| Iceland | 347 | 12.4 | 8.4 | 5.7 | 5.4 | 11.2 |
| Norway | 330 | 12.2 | 8.0 | 5.9 | 5.9 | 12.1 |
| Sweden | 717 | 9.8 | 7.8 | 4.0 | 6.7 | 10.7 |
| Estonia | 105 | 7.6 | 2.9 | 4.8 | 7.6 | 8.6 |
| Belgium | 286 | 3.5 | 1.5 | 3.6 | 4.9 | 5.6 |
| Germany | 377 | 11.4 | 3.6 | 4.4 | 8.0 | 8.8 |
| France | 889 | 12.3 | 7.1 | 4.7 | 6.8 | 12.5 |
| UK | 249 | 13.3 | 12.4 | 2.0 | 3.6 | 12.8 |
| Italy | 226 | 9.7 | 4.0 | 0 | 4.0 | 6.6 |
| Spain | 872 | 7.9 | 3.7 | 3.6 | 4.6 | 6.7 |
| Australia | 219 | 16.9 | 10.7 | 8.0 | 8.5 | 15.5 |
| p-value | <0.0001 | <0.0001 | 0.003 | 0.13 | <0.0001 |
Data are presented as n, unless otherwise stated. SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid. #: as single inhalers or in combination.